Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Life (Basel) · 2023 · PMC10817256 · PMID 38255638

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The trial showed a trend for a PFS survival benefit; however, this was not statistically significant (PFS 10 months vs. 5.7 months, HR 0.75, p = 0.08), which was the primary endpoint [ 54 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.